Hao Chen

Hao Chen

Auto-generated profile, based on publicly available information

Hao Chen

School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ASAparna Shinde
Aparna Shinde
TWTomasz Wilmanski
Tomasz Wilmanski
HCHao Chen
Hao Chen
DTDorothy Teegarden
Dorothy Teegarden
MWMichael Wendt
Michael Wendt
Overcoming systemic dormancy and initiating secondary tumor grow under unique microenvironmental conditions is a major rate-limiting step in metastatic progression. Disseminated tumor cells encounter major changes in nutrient supplies and oxidative stresses compared to the primary tumor and must demonstrate significant metabolic plasticity to adapt to specific metastatic sites. Recent studies suggest that differential utilization of pyruvate sits as a critical node in determining the organotropism of metastatic breast cancer. Pyruvate carboxylase (PC) is key enzyme that converts pyruvate into oxaloacetate for utilization in gluconeogenesis and replenishment of the TCA cycle. Patient survival was analyzed with respect to gene copy number alterations and differential mRNA expression levels of PC. Expression of PC was analyzed in the MCF-10A, D2-HAN and the 4 T1 breast cancer progression series under in vitro and in vivo growth conditions. PC expression was depleted via shRNAs and the impact on in vitro cell growth, mammary fat pad tumor growth, and pulmonary and non-pulmonary metastasis was assessed by bioluminescent imaging. Changes in glycolytic capacity, oxygen consumption, and response to oxidative stress were quantified upon PC depletion. Genomic copy number increases in PC were observed in 16–30% of metastatic breast cancer patients. High expression of PC mRNA was associated with decreased patient survival in the MCTI and METABRIC patient datasets. Enhanced expression of PC was not recapitulated in breast cancer progression models when analyzed under glucose-rich in vitro culture conditions. In contrast, PC expression was dramatically enhanced upon glucose deprivation and in vivo in pulmonary metastases. Depletion of PC led to a dramatic decrease in 4 T1 pulmonary metastasis, but did not affect orthotopic primary tumor growth. Tail vein inoculations confirmed the role of PC in facilitating pulmonary, but not extrapulmonary tumor initiation. PC-depleted cells demonstrated a decrease in glycolytic capacity and oxygen consumption rates and an enhanced sensitivity to oxidative stress. Our studies indicate that PC is specifically required for the growth of breast cancer that has disseminated to the lungs. Overall, these findings point to the potential of targeting PC for the treatment of pulmonary metastatic breast cancer.

8 October 2020 in Oncogene
Verified
Journal Article
Open access
PDF file
HCHao Chen
Hao Chen
SLSarah Libring
Sarah Libring
KRKasi Viswanatharaju Ruddraraju
Kasi Viswanatharaju Ruddraraju
JMJinmin Miao
Jinmin Miao
LSLuis Solorio
Luis Solorio
MWMichael Wendt
Michael Wendt
Metastatic breast cancer (MBC) is an extremely recalcitrant disease capable of bypassing current targeted therapies via engagement of several growth promoting pathways. SH2 containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase known to facilitate growth and survival signaling downstream of numerous receptor inputs. Herein, we used inducible genetic depletion and two distinct pharmacological inhibitors to investigate the therapeutic potential of targeting SHP2 in MBC. Cells that acquired resistance to the ErbB kinase inhibitor, neratinib, displayed increased phosphorylation of SHP2 at the Y542 activation site. In addition, higher levels of SHP2 phosphorylation, but not expression, were associated with decreased survival of breast cancer patients. Pharmacological inhibition of SHP2 activity blocked ERK1/2 and AKT signaling generated from exogenous stimulation with FGF2, PDGF, and hGF and readily prevented MBC cell growth induced by these factors. SHP2 was also phosphorylated upon engagement of the extracellular matrix (ECM) via focal adhesion kinase. Consistent with the potential of SHP2-targeted compounds as therapeutic agents, the growth inhibitory property of SHP2 blockade was enhanced in ECM-rich 3D culture environments. In vivo blockade of SHP2 in the adjuvant setting decreased pulmonary metastasis and extended the survival of systemic tumor-bearing mice. Finally, inhibition of SHP2 in combination with FGFR-targeted kinase inhibitors synergistically blocked the growth of MBC cells. Overall, our findings support the conclusion that SHP2 constitutes a shared signaling node allowing MBC cells to simultaneously engage a diversity of growth and survival pathways, including those derived from the ECM.

26 August 2019 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AKAaron Krabill
Aaron Krabill
HCHao Chen
Hao Chen
SHSajjad Hussain
Sajjad Hussain
CFChao Feng
Chao Feng
AAAmmara Abdullah
Ammara Abdullah
DFDaniel P. Flaherty
Daniel P. Flaherty

16 June 2015 in Cancer Science
Verified
Journal Article
Open access
PDF file
ZLZheqi Li
Zheqi Li
QZQi Zhu
Qi Zhu
LHLingyun Hu
Lingyun Hu
HCHao Chen
Hao Chen
ZWZhenghua Wu
Zhenghua Wu
DLDawei Li
Dawei Li
Hypoxia inducible factor‐1α (HIF‐1α) is associated with human breast cancer chemoresistance. Various reports have suggested that multiple pathways are involved inHIF‐1α induction and that the molecular mechanisms regulatingHIF‐1α‐induced chemoresistance are still not fully understood. Here, we report that anterior gradient 2 (AGR2), a proposed breast cancer biomarker, is an essential regulator in hypoxia‐induced doxorubicin resistance through the binding and stabilization ofHIF‐1α. Our results show that knockdown ofAGR2 inMCF‐7 cells leads to the suppression ofHIF‐1α‐induced doxorubicin resistance, whereas elevated levels ofAGR2 inMDA‐MB‐231 cells enhanceHIF‐1α‐induced doxorubicin resistance.AGR2 expression, in turn, is upregulated by the hypoxic induction ofHIF‐1α at both translational and transcriptional levels via a hypoxia‐responsive region from −937 to −912 bp on theAGR2 promoter sequence. By specific binding toHIF‐1α, the increased level of intracellularAGR2 stabilizesHIF‐1α and delays its proteasomal degradation. Finally, we found thatAGR2‐stabilizedHIF‐1α escalates multiple drug resistance protein 1 (MDR1)mRNAlevels and limits doxorubicin intake ofMCF‐7 cells, whereasMCF‐7/ADR, a doxorubicin resistant cell line with deficientAGR2 andHIF‐1α, acquires wild‐typeMDR1 overexpression. Our findings, for the first time, describeAGR2 as an important regulator in chemical hypoxia‐induced doxorubicin resistance in breast cancer cells, providing a possible explanation for the variable levels of chemoresistance in breast cancers and further validatingAGR2 as a potential anti‐breast cancer therapeutic target.

1 July 2016 in Cancer Letters
Verified
Journal Article
Closed access
ZLZheqi Li
Zheqi Li
QZQi Zhu
Qi Zhu
HCHao Chen
Hao Chen
LHLingyun Hu
Lingyun Hu
HNHema Negi
Hema Negi
DLDawei Li
Dawei Li

1 June 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HGHao Guo
Hao Guo
HCHao Chen
Hao Chen
QZQi Zhu
Qi Zhu
XYXiaoyan Yu
Xiaoyan Yu
RRRong Rong
Rong Rong
DLDawei Li
Dawei Li